While coronary artery disease (CAD) patients with both ischemia and angina proved to have higher risks for mortality, 58.2 percent of patients without symptoms died of cardiovascular- or MI-related causes, according to a study published online Aug. 11 in JAMA: Internal Medicine.

Physicians monitoring heart transplant patients rely on frequent endomyocardial biopsies to detect nonsymptomatic rejection. But for how long? One year may be sufficient, a cost-effectiveness analysis concluded. 

InspireMD, Inc., a leader in embolic protection systems, today announced that Professor Joachim Schofer, MD, at the Hamburg University Cardiovascular Center, will present the results of the CARENET (CARotid Embolic protection using microNET) trial at the Transcatheter Cardiovascular Therapeutics (TCT) conference, in Washington, D.C. on Tuesday September 16, 2014.

Meet retired electrophysiologist David Mann, MD, not to be confused with all the other doctors with the same name. Except unfortunately for him, he was, and in the one of the thorniest places imaginable—the Centers for Medicare & Medicaid Services’ Open Payments System. 

The ablation market is expected to top $10 billion by 2020, according to Transparency Market Research, with radiofrequency ablation leading the charge.

Muscle physiologist Edward Debold at the University of Massachusetts Amherst's School of Public Health and Health Sciences recently received a three-year, $198,000 grant from the American Heart Association to support studies to uncover the molecular mechanisms of skeletal muscle fatigue.

The FDA approved a quadripolar lead and two cardiac resynchronization therapy-defibrillator (CRT-D) devices for treatment in patients with heart failure.

Counter to current guidelines in some countries where it is used, intravenous alteplase has been shown to be effective in stroke patients irrespective of age up to 4.5 hours after stroke onset, according to a study published online Aug. 6 in The Lancet. However, for best outcomes, speed was important.